Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
Lieberman, R.L., Wustman, B.A., Huertas, P., Powe, A.C., Pine, C.W., Khanna, R., Schlossmacher, M.G., Ringe, D., Petsko, G.A.(2007) Nat Chem Biol 3: 101-107
- PubMed: 17187079 
- DOI: 10.1038/nchembio850
- Primary Citation of Related Structures:  
2NSX, 2NT0, 2NT1 - PubMed Abstract: 
Gaucher disease results from mutations in the lysosomal enzyme acid beta-glucosidase (GCase). Although enzyme replacement therapy has improved the health of some affected individuals, such as those with the prevalent N370S mutation, oral treatment with pharmacological chaperones may be therapeutic in a wider range of tissue compartments by restoring sufficient activity of endogenous mutant GCase ...